Research progress of non-coding RNA in multiple myeloma

doi:10.3969/j.issn.1673-8640.2018.03.017

Abstract

Abstract:

Non-coding RNA （ncRNA）is a class of RNA with a few or no capacity of protein synthesis. It includes microRNA （miRNA）and long non-coding RNA （lncRNA）. MiRNA is the shortest ncRNA expressed aberrantly in solid and hematopoietic malignancies,where it plays a pivotal function as post-transcriptional regulators of gene expression. LncRNA has been shown to be expressed aberrantly in cancer tissue and to be involved in oncogenic or tumor suppressive process in mammalian and human. This review mainly describes the biological function and potential therapeutic role of ncRNA as drug or target.

Key words: Non-coding RNA, Multiple myeloma, Pathology, Biomarker, Therapy

CLC Number:

R446.1

JI Wei, WU Hongkun, ZHOU Lin. Research progress of non-coding RNA in multiple myeloma[J]. Laboratory Medicine, 2018, 33(3): 264-268.

References 35

1	BIANCHI G, ANDERSON K C. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back[J]. CA Cancer J Clin, 2014,64(6): 422-444.
2	ALLART-VORELLI P, PORRO B, BAGUET F, et al. Haematological cancer and quality of life: a systematic literature review[J]. Blood Cancer J, 2015,5: e305.
3	MITSIADES C S, MITSIADES N, MUNSHI N C, et al. Focus on multiple myeloma[J]. Cancer Cell, 2004,6(5): 439-444.
4	KUMAR S K, RAJKUMAR S V, DISPENZIERI A, et al. Improved survival in multiple myeloma and the impact of novel therapies[J]. Blood, 2008,111(5): 2516-2520.
5	BERTONE P, STOLC V, ROYCE T E, et al. Global identification of human transcribed sequences with genome tiling arrays[J]. Science, 2004,306(5705): 2242-2246.
6	International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome[J]. Nature, 2004,431(7011): 931-945.
7	AMBROS V. The functions of animal microRNAs[J]. Nature, 2004, 431(7006): 350-355.
8	YU Z, TOZEREN A, PESTELL R G. Function of miRNAs in tumor cell proliferation[J]. Springer Netherlands, 2013,431(7006): 13-27.
9	MERCER T R, DINGER M E, MATTICK J S. Long non-coding RNAs: insights into functions[J]. Nat Rev Genet, 2009,10(3): 155-159.
10	PONTING C P, OLIVER P L, REIK W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009,136(4): 629-641.
11	KORNIENKO A E, GUENZL P M, BARLOW D P, et al. Gene regulation by the act of long non-coding RNA transcription[J]. BMC Biol, 2013,11: 59.
12	FATICA A, BOZZONI L. Long non-coding RNAs: new players in cell differentiation and development[J]. Nat Rev Genet, 2014,15(1): 7-21.
13	WANG X, LI C, WANG Y, et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation[J]. Leuk Lymphoma, 2011,52(10): 1991-1998.
14	ROCCARO A M, SACCO A, THOMPSON B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma[J]. Blood, 2009,113(26): 6669-6680.
15	SAITO Y, LIANG G, EGGER G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells[J]. Cancer Cell, 2006,9(6): 435-443.
16	BANDRES E, AGIRRE X, BITARTE N, et al. Epigenetic regulation of microRNA expression in colorectal cancer[J]. Int J Cancer, 2009,125(11): 2737-2743.
17	BALLABIO E, MITCHELL T, VAN KESTER M S, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential[J]. Blood, 2010,116(7): 1105-1113.
18	WONG K Y, LIANG R, SO C C, et al. Epigenetic silencing of MIR203 in multiple myeloma[J]. Br J Haematol, 2011,154(5): 569-578.
19	ZHANG W, WANG Y E, ZHANG Y, et al. Global epigenetic regulation of microRNAs in multiple myeloma[J]. PLoS One, 2014,9(10): e110973.
20	MIN D J, EZPONDA T, KIM M K, et al. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC[J]. Leukemia, 2013,27(3): 686-694.
21	HAO M, ZHANG L, AN G, et al. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells[J]. J Hematol Oncol, 2011,4:37.
22	ROCCARO A M, SACCO A, MAISO P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression[J]. J Clin Invest, 2013,123(4): 1542-1555.
23	RONCHETTI D, AGNELLI L, TAIANA E, et al. Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma[J]. Oncotarget, 2016,7(12): 14814-14830.
24	SUN C Y, SHE X M, QIN Y, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF[J]. Carcinogenesis, 2013,34(2): 426-435.
25	PICHIORRI F, SUH S S, LADETTO M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis[J]. Proc Natl Acad Sci U S A, 2008,105(35): 12885-12890.
26	JONES C I, ZABOLOTSKAYA M V, KING A J, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma[J]. Br J Cancer, 2012,107(12): 1987-1996.
27	KUBICZKOVA L,KRYUKOV F,SLABY O,et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance[J]. Haematologica, 2014,99(3): 511-518.
28	ZHUANG W, GE X, YANG S, et al. Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription[J]. Stem Cells, 2014,33(6):1985-1997.
29	CHO S F, CHANG Y C, CHANG C S, et al. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression[J]. BMC Cancer, 2014,14: 809.
30	ZHOU M, ZHAO H, WANG Z, et al. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma[J]. J Exp Clin Cancer Res, 2015,34: 102.
31	AMODIO N, DI MARTINO M T, FORESTA U, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1[J]. Cell Death Dis, 2012,3: e436.
32	LÖFFLER D, BROCKE-HEIDRICH K, PFEIFER G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer[J]. Blood, 2007,110(4): 1330-1333.
33	LEONE E, MORELLI E, DI MARTINO M T, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth[J]. Clin Cancer Res, 2013,19(8): 2096-2106.
34	PICHIORRI F, SUH S S, ROCCI A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development[J]. Cancer Cell, 2010,18(4): 367-381.
35	ROCCARO A M, SACCO A, MAISO P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression[J]. J Clin Invest, 2013,123(4): 1542-1555.

[1]	SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury [J]. Laboratory Medicine, 2023, 38(8): 784-789.
[2]	GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679.
[3]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[4]	ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598.
[5]	YU Qi, WANG Yanchun, GUO Lin, LU Renquan. Influence of particle radiotherapy on bone marrow，liver and kidney functions in patients with prostate cancer [J]. Laboratory Medicine, 2023, 38(5): 430-434.
[6]	GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306.
[7]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[8]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[9]	ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210.
[10]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[11]	GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996.
[12]	LU Qiyuan, LU Jianhua. Biomarker research progress for the diagnosis of periprosthetic joint infection [J]. Laboratory Medicine, 2023, 38(10): 997-1002.
[13]	CHEN Xuewei, LI Yirong. Candidate biomarkers in metabolic syndrome based on GEO database [J]. Laboratory Medicine, 2023, 38(1): 32-38.
[14]	WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45.
[15]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.